Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
